mprovement of the treatment of tendon injury is an issue of central concern within the field of orthopaedic surgery. The current management of Achilles tendon ruptures focuses on the mechanical aspects of healing. Clinicians weigh their options for achieving and maintaining apposition of the ruptured ends of the tendon against their concerns about muscular atrophy, rerupture, and complications of treatment [1] [2] [3] [4] [5] [6] . Surgical management directly repairs the tendon, permits early initiation of rehabilitation, and reduces the rate of rerupture. However, nerve injury, dehiscence, infection, and scarring at the site of the wound may compromise the outcomes of treatment. Immobilization with a cast or functional bracing obviates the risks attendant with surgical repair but increases the chance of a rerupture and may prolong the need for ther-I Disclosure: In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants of less than $10,000 from the Orthopaedic Research and Education Foundation, the American Orthopaedic Foot and Ankle Society, and the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.
apy to address muscular atrophy and stiffness of the joints. All of these options rely on, but do not capitalize on, the complex biological milieu that governs tendon-healing. The introduction of new strategies to manipulate these molecular and cellular interactions to enhance healing and function may yield more successful outcomes of the treatment of these injuries.
Several studies have focused on the effects of bone morphogenetic proteins (BMPs) on healing tendons. BMP-12, 13, and 14 have been shown to induce neotendon formation in animal models when injected ectopically 7, 8 . Direct injection of each of these three proteins increased the tensile strength of the reparative tendon that formed in the defects of rat and rabbit Achilles tendon rupture models [9] [10] [11] [12] [13] . Similar effects on tensile strength have been observed in flexor-tendon-laceration chicken and rabbit models [14] [15] [16] . In these experimental models of protein therapy, the BMP is delivered to the local environment through a carrier. The carrier facilitates sustained release of the protein to maintain an optimal concentration at the site of healing. However, the therapeutic effect of protein therapy diminishes over time as the quantity of delivered BMP diffuses into the surrounding tissue. Gene therapy potentially obviates the need for a carrier and addresses the problem of diffusion. This system delivers the gene for the BMP directly to the site of injury. The gene may be transferred into host cells, or exogenous cells containing the gene may be introduced directly, to establish a constant source for the local production of BMP through gene expression.
The favorable effects on tendon-healing observed after the direct injection of BMP encouraged us to evaluate the capacity of BMP gene therapy to enhance healing of an Achilles tendon laceration. Our previous experience with the effects of adenovirus-mediated BMP gene transfer on flexor tendon repair suggested that the use of this viral delivery system would permit the expression of human BMP-14 (AdBMP-14) at the site of an Achilles tendon laceration 17 . In the present study, we hypothesized that AdBMP-14 is an effective delivery system for gene therapy in a rat model of an Achilles tendon laceration. We also hypothesized that transgene expression of BMP-14 at the site of injury would improve the histological appearance and biomechanical strength of a surgical repair of an Achilles tendon laceration when compared with controls.
Materials and Methods

Construction and Preparation of Recombinant
Adenovirus Vector Expressing BMP-14 and Green Fluorescent Protein Controls e previously described our technique for generating recombinant adenoviral vectors expressing human BMPs for gene therapy [18] [19] [20] [21] . Briefly, the coding region of the human BMP-14 gene was amplified with use of a polymerase-chainreaction process and subcloned into an adenoviral shuttle vector (pAdTrack-CMV). Once the integrity of the amplified human BMP-14 gene was verified by DNA sequencing, a recombinant adenovirus plasmid was constructed and subsequently transfected into an HEK 293 cell line to generate high-titer stocks of adenovirus expressing BMP-14 (AdBMP-14). The AdBMP-14 also encoded the gene expressing a green fluorescent protein (GFP) to serve as a marker for infection. With use of an identical process, an adenovirus expressing only green fluorescent protein (AdGFP) was constructed as a control for the effects of adenoviral infection of the cells at the site of tendon repair.
Assignment of Treatment and Control Groups
The institutional animal care and use committee of the University of Chicago approved the protocol governing the use and care of the animals in this study. Ninety seven-week-old male Sprague-Dawley rats were divided into three groups of thirty animals each. One group of animals received the adenovirus expressing GFP and BMP-14 (AdBMP-14, 10 8 plaqueforming units [pfu] per injection) at the site of the repaired tendon. The second group received the adenovirus expressing only GFP (AdGFP, 10 8 pfu per injection). The third (surgical control) group received no virus after repair of the tendon. The doses of the adenoviruses used in this investigation were based on our previous work 17, 18, 20, 21 and the results of a pilot study with our animal model.
Ten rats from each group were killed at one, two, and three weeks after surgical repair. The entire Achilles tendon with the attached gastrocnemius muscle body and the proximal half of the calcaneus were harvested en bloc. Eight tendons from each of the nine subgroups underwent biomechanical testing immediately after the animals were killed. Two tendons from each subgroup were designated for histological examination.
Achilles Tendon Laceration and Surgical Repair
Each rat was anesthetized with isoflurane delivered through a mask and a chambered gas-anesthesia machine. A posterior midline incision was made over the right hindpaw of each rat to the level of the peritenon. The peritenon was identified and was incised in line with the skin. The Achilles and plantaris tendons were isolated, and the Achilles tendon was sharply transected at a point halfway between the musculotendinous junction and the insertion onto the calcaneus. The plantaris muscle and tendon were preserved throughout the procedure.
Each end of the transected tendon was injected with an aliquot of its designated viral suspension (10 8 pfu in 10 µL). The animals in the surgical control group received no injection. A single, 6-0 horizontal mattress Ticron suture (Syneture, Norwalk, Connecticut) was used to appose the tendon ends. Skin was apposed with veterinary surgical clips. Each rat recovered from the anesthesia alone in a cage under a warming lamp and received a single subcutaneous injection of buprenorphine (50 µg/kg) for pain control after the surgery. The rats were then housed in pairs, allowed to eat, drink, and move ad libitum, and monitored on a daily basis until they were killed.
Histological Analysis
Immediately after harvest, one tendon from each subgroup was processed and was examined with fluorescent microscopy to evaluate the extent of adenovirus-mediated gene transfer to host cells. Another tendon from each subgroup was decalci-W fied, thin-sectioned in the coronal plane, and stained with hematoxylin and eosin. Microscopic slides were evaluated for the presence of an inflammatory host response, ectopic bone or cartilage formation, and the appearance of the reparative tissue formed at the site of the tendon repair independently by at least three investigators blinded to the group assignments.
Assessment of Gapping of the Retrieved Samples
The remaining eight tendons from each subgroup were designated for mechanical testing, and the site of repair was inspected for gapping. The location of tendon apposition was defined as the region between the cephalad and caudad passage of the horizontal mattress suture through the tendon. Two observers blinded to group assignment independently measured the gap once with a metric ruler. Gapping was defined as a distance of >1 mm between the healed ends of the proximal and distal tendon stumps. Each observer recorded the presence or absence of gapping for each repair in a separate table for subsequent comparison.
Biomechanical Analysis
The ultimate tensile strength of each repair was determined with use of a published methodology established for the biomechanical testing of healing lacerations of Achilles tendons in rats 12, 13, [22] [23] [24] [25] [26] . Briefly, each specimen was mounted on a tensiometer. At the distal end of the specimen, the calcaneus was fixed with a clamp positioned at a 30° angle to the direction of the applied load, and the proximal end of the specimen was clamped at the musculotendinous junction. Before the initiation of testing, the plantaris tendon was transected to isolate loading to the repaired Achilles tendon. The tensile load was applied at a constant rate of 1 mm/sec until failure. The ultimate load to failure was recorded for each specimen.
Statistical Analysis
We used analysis of variance to test whether there was a significant difference across the three treatment groups for the three time-points separately. If the F test in the analysis of variance showed a significant difference across the groups, additional pairwise comparisons were conducted. We were interested in two comparisons: between the AdBMP and sham groups and between the AdBMP and AdGFP groups. The stepdown Bonferroni procedure was used to control the family-wide type-I error rate.
Results
ecombinant adenoviruses expressing human BMP-14 (i.e., AdBMP-14) or GFP only (i.e., AdGFP) were constructed with the AdEasy system (Stratagene, La Jolla, California) 17, 18, 20, 21 (Fig. 1, A) . The AdBMP-14 also expresses GFP as a convenient marker to monitor gene transduction efficiency (Fig. 1, B) . As shown in Figure 1 , C, the AdBMP-14 infected the rat Achilles tendons, as an expression of the GFP was observed in the AdBMP-14 and AdGFP groups. At one week after surgery, the tendons in all three groups demonstrated gapping at the site of repair. At two weeks, most of the tendons in the AdBMP-14 group had robust healing with little or no gapping at the site of repair (six of eight had no gapping compared with two of eight and zero of eight in the AdGFP and sham groups, respectively), whereas the AdGFP and control groups did not demonstrate this quality of healing until three weeks after surgery (Fig. 2) .
Histological examination revealed no evidence of an acute inflammatory response to the adenoviral vectors in the tendons that received either AdBMP-14 or AdGFP (Fig. 3) . No ectopic bone or cartilage formation was observed in any of the tendons from these two groups (Fig. 3) .
The tendons treated with AdBMP-14 exhibited the highest tensile strength at one, two, and three weeks after surgery (Table I) . However, the difference was significant only at the two-week time-point, when the repaired tendons in the AdBMP-14 group were approximately 70% stronger than those in the AdGFP and sham groups (p = 0.012 and p = 0.018, respectively) ( Table I) . No significant difference in the strength of the repaired tendons was detected between the control and AdGFP groups at any of the three time-points.
Discussion
n this study, adenoviral-mediated gene therapy with BMP-14 enhanced the healing of a lacerated Achilles tendon repaired with surgery in a rat model. The tensile strength of the repaired tendons transduced with the recombinant BMP-14 gene was 70% greater than that in either control group at two weeks after surgery. This increase in strength at two weeks coincided with the observed difference in the gross and histological appearance of the healing tendons. The tendons infected with AdBMP-14 had less gapping and a greater number of neotenocytes at the site of the repair than did the viral and surgical control groups. These results suggest that BMP-14 may stimulate a more active cellular response to tendon injury.
The biomechanical results suggest that the expression of the BMP-14 transgene by the host tenocytes accelerates the cellular processes of tendon-healing. Under our testing conditions, an intact Achilles tendon failed at a mean load of 36 N. The mean tensile strength of the tendons from the two control groups approached the intact condition when their load to failure doubled between the second and third week after repair. The loads to failure of the tendons exposed to BMP-14 doubled, and three-fourths of their normal tensile strength was restored, I Fig. 2 Macrographic examination of the retrieved Achilles tendons from the sham (A), AdGFP (B), and AdBMP-14 (C) groups at two weeks after surgery showed less gapping in those treated with AdBMP-14. between the first and second weeks. Their mean load to failure attained the value for the intact tendon by the third week after repair. These results suggest that BMP-14 is an effective adjuvant to the indigenous reparative process of tendon-healing. The magnitude of the difference in strength that we observed in rat Achilles tendons is comparable with the results following use of BMP-12 gene therapy to enhance healing of flexor tendons in chickens 15 . Although the rat model for Achilles tendon injury was well established in several previous studies 9, 10, 12, 13 , the comparison of our results with the chicken flexor tendon model is confounded by two factors. The presence of a comparatively large plantaris tendon may act as an internal splint during nascent healing of the adjacent Achilles tendon, especially during quadrupedal gait. Also, the lack of a true tenosynovial envelope around the Achilles tendon may alter the reparative environment as compared with that of an injured flexor tendon. However, preservation of the plantaris tendon during healing may better represent the conditions associated with a rupture of the Achilles tendon in the clinical setting.
The formation of bone or cartilage has been a concern with the use of BMPs to augment tendon-healing. The induction of bone or cartilage formation within the tendon has been observed primarily with recombinant-protein-injection models 10, 11, 13 . Investigators using adenoviral gene-therapy models have not reported ectopic bone or cartilage formation 14, 15 . In the present study, histological examination of one tendon in each group at all time-points revealed no evidence of bone or cartilage. Thus, the results of this study suggest that adenoviral delivery of BMP-14 does not induce ectopic bone or cartilage formation in injured and repaired Achilles tendons of rats.
Limitations associated with the healing and testing of rat tendons should be considered when the results of this investigation are interpreted. A lacerated rat Achilles tendon heals within three weeks. This robust reparative process and short time-interval in which to observe alterations in healing may have diminished our capacity to observe the full effect of gene therapy on tensile strength. The inclusion of additional time-points spaced at shorter intervals during healing may have permitted a more extensive characterization of the effects of AdBMP-14 on the biomechanical properties of a repaired Achilles tendon laceration. Also, we employed a continuous load to failure to test the freshly harvested tendons. Although a cyclical load would have been the preferred method of test- Histological evaluation of the retrieved tendon tissues, which were fixed in 10% formalin and subjected to paraffin-embedding. Five-micrometer sections were prepared for hematoxylin and eosin staining (magnification, ×200).
ing, difficulties encountered with mounting the specimens in a consistent manner to maintain a firm grip without slippage or tearing during testing prevented the use of a cyclical load. In addition, we did not precondition our fresh specimens before testing, as preconditioning was not included in the continuous-loading protocol described by Forslund and Aspenberg 12 . The testing of fresh tendons that have not undergone a freeze-thaw under a slow continuous load mitigates the effect of viscoelasticity on the ultimate load to failure. Although the use of continuous, rather than a cyclical, loading and the omission of preconditioning may alter the load at which a tendon fails, this effect was presumably uniform throughout the population of specimens tested in our study. Under these conditions, the testing protocol that we employed in our study is unlikely to have affected the differences observed among the groups during biomechanical testing.
The results of this study indicate that adenoviral-mediated BMP-14 transgene expression improves tendon-healing at the site of the repair. Future studies of more advanced animal models are warranted to further our understanding of the effects of BMP-14 with regard to the biologic augmentation of tendon repair.
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